Functional experiments using CRISPR-Cas9 knockout demonstrate that METTL16 depletion significantly inhibits AML initiation, progression, and maintenance, markedly reducing LSC/LIC self-renewal while minimally affecting normal hematopoiesis (28). This evidence concerns the gene METTL16 and acute myeloid leukemia.